NeoGenomics (NEO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), Trevi Therapeutics (TRVI) and DENTSPLY SIRONA (XRAY)
BofA Securities Maintains NeoGenomics(NEO.US) With Hold Rating, Announces Target Price $18
NeoGenomics Hold Rating Maintained Amidst Ongoing Legal Challenges and MRD Assay Development Uncertainty
Needham Maintains NeoGenomics(NEO.US) With Buy Rating, Maintains Target Price $19
Needham analyst Michael Matson maintains $NeoGenomics(NEO.US)$ with a buy rating, and maintains the target price at $19.According to TipRanks data, the analyst has a success rate of 43.6% and a
Craig-Hallum Maintains NeoGenomics(NEO.US) With Buy Rating
Craig-Hallum analyst Matt Hewitt maintains $NeoGenomics(NEO.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 41.6% and a total average return of -3.9% over the